FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2524880168> ?p ?o ?g. }

• W2524880168 abstract "Abstract Abstract 1751 Background: The addition of rituximab to CHOP (R-CHOP) has markedly improved the progression-free and overall survival of patients (pts) with diffuse large B cell lymphoma (DLBCL). Nevertheless, 9.5% of pts harbor lymphoma that is refractory to R-CHOP (Feugier et al) and 18–27% experience relapse after initial response (GELA and MINT trial). Aim: Assess outcome of pts with primary refractory and early relapsing DLBCL (within 3 months of CR/PR post completion of R-CHOP treatment). Patients and Methods: The BCCA Lymphoid Cancer Database identified 1126 pts diagnosed with DLBCL between December 2000 and September 2009. All ages and stages were included and primary treatment was R-CHOP in all pts. Results: 166 pts(15%) had primary refractory or early relapsing disease, of which 93 were age >70 y and too frail to have received > 2 cycles of R-CHOP. Of the remaining 73 pts, 33 (45%) had primary refractory lymphoma and 40 (55 %) relapsed within 3 months of achieving a CR/PR. Pt characteristics (n=73): median age 57 y; 68% male; stage I (4 %), II (16 %), III (19 %), IV (60 %); PS 0,1 (41 %) PS 2–4 (59 %); LDH elevated (58 %); IPI 0 (1 %), 1 (15 %), 2 (15 %), 3 (30 %), 4 (35 %), 5 (2 %). There were no differences in the clinical characteristics of pts with primary refractory versus early relapsing disease. Of the 73 pts, 37 (50%) were without serious co-morbidity and were able to be treated with a curative intent that included multi-agent salvage chemotherapy with a plan to proceed to high-dose tx and autologous stem cell transplantation (ASCT), whereas 36 pts had palliative tx or comfort care only. 10 pts did undergo ASCT (3 primary refractory, 7 early relapsers). The median overall survival for the 73 pts was 10 months with only 6 pts alive without evidence of disease (range 14–106 months). 5 of these 6 pts had relapsed early after initial CR/PR, while only 1 patient had primary refractory disease. 3 of these 6 pts had salvage treatment without ASCT and 3 with ASCT. Conclusion: Chemotherapy-refractory or early relapsed disease after R-CHOP has a very poor outcome with only anecdotal survivors independent of the intended treatment approach. Biologic workup of this group of patients is urgently needed with the intention of defining the molecular underpinnings of treatment resistance. Disclosures: Savage: Roche: Honoraria. Sehn:Roche: Honoraria, Research Funding." @default.
• W2524880168 created "2016-10-07" @default.
• W2524880168 creator A5016787940 @default.
• W2524880168 creator A5017873196 @default.
• W2524880168 creator A5021276970 @default.
• W2524880168 creator A5022658681 @default.
• W2524880168 creator A5023202154 @default.
• W2524880168 creator A5026641386 @default.
• W2524880168 creator A5031758990 @default.
• W2524880168 creator A5037428122 @default.
• W2524880168 creator A5075117420 @default.
• W2524880168 date "2010-11-19" @default.
• W2524880168 modified "2023-09-30" @default.
• W2524880168 title "Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment" @default.
• W2524880168 doi "https://doi.org/10.1182/blood.v116.21.1751.1751" @default.
• W2524880168 hasPublicationYear "2010" @default.
• W2524880168 type Work @default.
• W2524880168 sameAs 2524880168 @default.
• W2524880168 citedByCount "4" @default.
• W2524880168 countsByYear W25248801682017 @default.
• W2524880168 countsByYear W25248801682020 @default.
• W2524880168 crossrefType "journal-article" @default.
• W2524880168 hasAuthorship W2524880168A5016787940 @default.
• W2524880168 hasAuthorship W2524880168A5017873196 @default.
• W2524880168 hasAuthorship W2524880168A5021276970 @default.
• W2524880168 hasAuthorship W2524880168A5022658681 @default.
• W2524880168 hasAuthorship W2524880168A5023202154 @default.
• W2524880168 hasAuthorship W2524880168A5026641386 @default.
• W2524880168 hasAuthorship W2524880168A5031758990 @default.
• W2524880168 hasAuthorship W2524880168A5037428122 @default.
• W2524880168 hasAuthorship W2524880168A5075117420 @default.
• W2524880168 hasConcept C121332964 @default.
• W2524880168 hasConcept C126322002 @default.
• W2524880168 hasConcept C141071460 @default.
• W2524880168 hasConcept C142424586 @default.
• W2524880168 hasConcept C2776694085 @default.
• W2524880168 hasConcept C2778559949 @default.
• W2524880168 hasConcept C2779338263 @default.
• W2524880168 hasConcept C2779714933 @default.
• W2524880168 hasConcept C2779725641 @default.
• W2524880168 hasConcept C2780653079 @default.
• W2524880168 hasConcept C71924100 @default.
• W2524880168 hasConcept C87355193 @default.
• W2524880168 hasConcept C90924648 @default.
• W2524880168 hasConceptScore W2524880168C121332964 @default.
• W2524880168 hasConceptScore W2524880168C126322002 @default.
• W2524880168 hasConceptScore W2524880168C141071460 @default.
• W2524880168 hasConceptScore W2524880168C142424586 @default.
• W2524880168 hasConceptScore W2524880168C2776694085 @default.
• W2524880168 hasConceptScore W2524880168C2778559949 @default.
• W2524880168 hasConceptScore W2524880168C2779338263 @default.
• W2524880168 hasConceptScore W2524880168C2779714933 @default.
• W2524880168 hasConceptScore W2524880168C2779725641 @default.
• W2524880168 hasConceptScore W2524880168C2780653079 @default.
• W2524880168 hasConceptScore W2524880168C71924100 @default.
• W2524880168 hasConceptScore W2524880168C87355193 @default.
• W2524880168 hasConceptScore W2524880168C90924648 @default.
• W2524880168 hasLocation W25248801681 @default.
• W2524880168 hasOpenAccess W2524880168 @default.
• W2524880168 hasPrimaryLocation W25248801681 @default.
• W2524880168 hasRelatedWork W1049067418 @default.
• W2524880168 hasRelatedWork W139931011 @default.
• W2524880168 hasRelatedWork W2058015212 @default.
• W2524880168 hasRelatedWork W2474937480 @default.
• W2524880168 hasRelatedWork W2499384225 @default.
• W2524880168 hasRelatedWork W2510572235 @default.
• W2524880168 hasRelatedWork W2525011819 @default.
• W2524880168 hasRelatedWork W2531290531 @default.
• W2524880168 hasRelatedWork W2536848274 @default.
• W2524880168 hasRelatedWork W2546775312 @default.
• W2524880168 hasRelatedWork W2552584997 @default.
• W2524880168 hasRelatedWork W2557249356 @default.
• W2524880168 hasRelatedWork W2559524585 @default.
• W2524880168 hasRelatedWork W2563179174 @default.
• W2524880168 hasRelatedWork W2567689975 @default.
• W2524880168 hasRelatedWork W2979645590 @default.
• W2524880168 hasRelatedWork W2979862471 @default.
• W2524880168 hasRelatedWork W2981226123 @default.
• W2524880168 hasRelatedWork W3016593962 @default.
• W2524880168 hasRelatedWork W978684921 @default.
• W2524880168 isParatext "false" @default.
• W2524880168 isRetracted "false" @default.
• W2524880168 magId "2524880168" @default.
• W2524880168 workType "article" @default.